《2017年ACR糖皮质激素性骨质疏松症防治指南》解读  

Interpretation of 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

作　　者：高颖 赵东宝 GAO Ying;ZHAO Dong-bao(Department of Rheumatology and Immunology,Changhai Hospital,Shanghai 200433,China)

机构地区：[1]长海医院风湿免疫科,上海市200433

出　　处：《中国全科医学》2018年第6期627-632,共6页Chinese General Practice

基　　金：上海领军人才队伍建设专项基金(201444)

摘　　要：糖皮质激素性骨质疏松症(GIOP)居继发性骨质疏松症的首位。糖皮质激素(GC)对骨量的影响持续存在且无安全阈值,任何时候进行防治均正当时。随着临床上获得了更多有关GIOP的临床特征、骨折风险评估、干预及随访等重要问题的证据和经验,2017年美国风湿病学会再次推出新版GIOP防治指南。本文总结了该指南中骨折风险分层、评估与再评估时机、初始与随访治疗策略、治疗药物优先顺序及普通/特殊人群的防治要点等重要内容,以期更新临床医师诊治GIOP的观念。Glucocorticoid-induced osteoporosis(GIOP)ranks first in secondary osteoporosis.The effect of glucocorticoids(GCs)on bone mass persists and there is no safety threshold.Therefore,prevention and treatment of GCs is always appropriate at any time.With more evidence and experience gained about clinically important features of GIOP,its fracture risk assessment and better decisions during intervention period and follow-up,the American College of Rheumatology again launched the new GIOP guidelines in 2017.This article summarized the fracture risk stratification,timing of assessment and reassessment,initial and follow-up treatment strategies for general/special populations in order to update notion of clinicians treating GIOP.

关 键 词：骨质疏松 糖皮质激素类 骨折 指南 

分 类 号：R681[医药卫生—骨科学]